This clinical trial is focused on studying the effects of certain medications on Cancer. The medications being tested include AVELUMAB, LORLATINIB, AXITINIB, and TALAZOPARIB. AVELUMAB is a human antibody that targets a protein called PD-L1, which is involved in the immune system’s response to cancer. LORLATINIB is a small molecule that inhibits specific proteins known as ALK and ROS1 kinases, which can be involved in cancer growth. AXITINIB is a selective inhibitor of vascular endothelial growth factor (VEGF) receptors, which play a role in the formation of blood vessels that supply tumors. TALAZOPARIB is a potent, orally available small molecule that inhibits PARP, a protein involved in DNA repair.

The purpose of this study is to monitor the safety and tolerability of these treatments. Participants in this study will continue to receive the study medications they were already taking in previous trials. The study will involve regular visits to monitor the participants’ health and any side effects they may experience. The study is open-label, meaning both the participants and the researchers know which treatment is being administered. Some participants may receive a placebo, which is a substance with no active medication, to compare the effects of the actual drugs.

The study will last for a period of up to 60 months, during which participants will be closely monitored for any adverse effects or serious adverse events. The goal is to ensure that the treatments are safe and to gather more information about their effects on cancer. Participants will be required to follow specific guidelines and attend scheduled visits as part of the study protocol. This trial is part of a larger effort to understand and improve cancer treatments using these medications.